Precision Therapeutics to Hold Business Update Conference Call on August 14, 2018
August 08 2018 - 5:15PM
Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the
Company”), a company focused on applying artificial intelligence to
personalized medicine and drug discovery, announced today that
management will report its financial results for the fiscal second
quarter of 2018 on August 14, 2018 after U.S. markets close.
Management will also hold a conference call to provide a general
business update and discuss upcoming milestones. The conference
call is scheduled to begin at 4:30 p.m. Eastern Time. A webcast of
the event will be available via the ‘Investor Info’ section of the
Company’s website at http://www.precisiontherapeutics.com/.
To access the conference call, U.S.-based listeners should dial
+1 (866) 548-4713 and international listeners should dial +1 (323)
794-2093. All listeners should provide the following passcode:
5618301.
A dial-in replay of the call will also be available to those
interested until August 28, 2018. To access the replay, dial
+1 (844) 512-2921 (United States) or +1 (412) 317-6671
(International) and enter replay pin number: 5618301.
To be added to the Precision Therapeutics’ database, please
email Info@MoneyInfo-llc.com with your email address. This is
solely for the use of Precision Therapeutics and will not be sold
or distributed to third parties.
About Precision Therapeutics Inc.
Precision Therapeutics (NASDAQ: AIPT) operates in two business
areas: first, applying artificial intelligence to personalized
medicine and drug discovery to provide personalized medicine
solutions for patients and clinicians as well as clients in the
pharmaceutical, diagnostic, and biotech industries, and second,
production of the FDA-approved STREAMWAY® System for
automated, direct-to-drain medical fluid disposal. For additional
information, please
visit www.precisiontherapeutics.com.Precision
Therapeutics’ medicine business is committed to improving the
effectiveness of cancer therapy using the power of artificial
intelligence (AI) applied to rich data diseases databases. This
business has launched with Precision
Therapeutics' investment in Helomics Corporation, a
precision medicine company and integrated clinical contract
research organization whose mission is to improve patient care by
partnering with pharmaceutical, diagnostic, and academic
organizations to bring innovative clinical products and
technologies to the marketplace. In addition to its
proprietary precision diagnostics for oncology, Helomics offers
boutique CRO services that leverage their patient-derived tumor
models, coupled to a wide range of multi-omics assays (genomics,
proteomics and biochemical), and a proprietary bioinformatics
platform (D-CHIP) to provide a tailored solution to our client's
specific needs. Helomics is 25% owned by Precision
Therapeutics. Helomics® is headquartered in Pittsburgh,
Pennsylvania where the company maintains state-of-the-art,
CLIA-certified, clinical and research laboratories. For more
information, please visit www.Helomics.com.Precision
Therapeutics has also announced the formation of a subsidiary,
TumorGenesis to pursue a new rapid approach to growing tumors in
the laboratory, which essentially “fools” the cancer cells into
thinking they are still growing inside the patient. Precision
Therapeutics and Helomics have also announced a proposed joint
venture with GLG Pharma focused on using their combined
technologies to bring personalized medicines and testing to ovarian
and breast cancer patients, especially those who present with
ascites fluid (over one-third of patients). The growth strategy in
this business includes securing new partnerships and considering
acquisitions in the precision medicine space.
Sold through the Skyline Medical business of Precision
Therapeutics, The STREAMWAY System virtually eliminates staff
exposure to blood, irrigation fluid and other potentially
infectious fluids found in the healthcare environment. Antiquated
manual fluid handling methods that require hand carrying and
emptying filled fluid canisters present an exposure risk and
potential liability. Skyline Medical's STREAMWAY System fully
automates the collection, measurement, and disposal of waste fluids
and is designed to: 1) reduce overhead costs to hospitals and
surgical centers; 2) improve compliance with OSHA and
other regulatory agency safety guidelines; 3) improve efficiency in
the operating room, and radiology and endoscopy departments,
thereby leading to greater profitability; and 4) provide greater
environmental stewardship by helping to eliminate the approximately
50 million potentially disease-infected canisters that go into
landfills each year in the U.S. For additional information,
please visit www.skylinemedical.com.
Contacts:Investor RelationsKCSA Strategic
CommunicationsElizabeth Barker(212) 896-1203ebarker@kcsa.com
MONEYINFO, LLCCharles
Moskowitz617-827-1296info@moneyinfo-llc.com
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Apr 2023 to Apr 2024